Delcath Systems Inc (DCTH) - Net Assets
Based on the latest financial reports, Delcath Systems Inc (DCTH) has net assets worth $111.22 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($123.63 Million) and total liabilities ($12.41 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Delcath Systems Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $111.22 Million |
| % of Total Assets | 89.96% |
| Annual Growth Rate | 23.2% |
| 5-Year Change | 830.55% |
| 10-Year Change | N/A |
| Growth Volatility | 536.26 |
Delcath Systems Inc - Net Assets Trend (1999–2025)
This chart illustrates how Delcath Systems Inc's net assets have evolved over time, based on quarterly financial data. Also explore how large is Delcath Systems Inc's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Delcath Systems Inc (1999–2025)
The table below shows the annual net assets of Delcath Systems Inc from 1999 to 2025. For live valuation and market cap data, see market value of Delcath Systems Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $111.22 Million | +61.78% |
| 2024-12-31 | $68.75 Million | +335.74% |
| 2023-12-31 | $15.78 Million | +369.28% |
| 2022-12-31 | $-5.86 Million | -149.02% |
| 2021-12-31 | $11.95 Million | -45.86% |
| 2020-12-31 | $22.08 Million | +447.30% |
| 2019-12-31 | $-6.36 Million | +57.45% |
| 2018-12-31 | $-14.94 Million | -2303.39% |
| 2017-12-31 | $678.00K | +145.50% |
| 2016-12-31 | $-1.49 Million | -117.32% |
| 2015-12-31 | $8.60 Million | -52.60% |
| 2014-12-31 | $18.14 Million | -39.72% |
| 2013-12-31 | $30.10 Million | +50.43% |
| 2012-12-31 | $20.01 Million | -23.35% |
| 2011-12-31 | $26.10 Million | -10.24% |
| 2010-12-31 | $29.08 Million | +22.40% |
| 2009-12-31 | $23.76 Million | +132.77% |
| 2008-12-31 | $10.21 Million | -37.87% |
| 2007-12-31 | $16.43 Million | +102.99% |
| 2006-12-31 | $8.09 Million | -35.76% |
| 2005-12-31 | $12.60 Million | +85.61% |
| 2004-12-31 | $6.79 Million | +212.73% |
| 2003-12-31 | $2.17 Million | +32.59% |
| 2002-12-31 | $1.64 Million | -49.29% |
| 2001-12-31 | $3.23 Million | -34.21% |
| 2000-12-31 | $4.91 Million | +901.11% |
| 1999-12-31 | $490.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Delcath Systems Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 51753800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $347.00K | 0.31% |
| Other Comprehensive Income | $575.00K | 0.52% |
| Other Components | $639.14 Million | 574.67% |
| Total Equity | $111.22 Million | 100.00% |
Delcath Systems Inc Competitors by Market Cap
The table below lists competitors of Delcath Systems Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mirbud SA
WAR:MRB
|
$334.81 Million |
|
SEONGAN CO. Ltd
KO:011300
|
$334.81 Million |
|
Fastighets AB Trianon (publ)
ST:TRIAN-B
|
$334.81 Million |
|
LUBAWA SA
WAR:LBW
|
$334.99 Million |
|
Cahya Mata Sarawak Bhd
KLSE:2852
|
$334.77 Million |
|
Bredband2 i Skandinavien AB
ST:BRE2
|
$334.75 Million |
|
FuelCell Energy Inc
NASDAQ:FCEL
|
$334.63 Million |
|
Aeris Resources Ltd
AU:AIS
|
$334.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Delcath Systems Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 68,746,000 to 111,219,000, a change of 42,473,000 (61.8%).
- Net income of 2,700,000 contributed positively to equity growth.
- Share repurchases of 6,000,000 reduced equity.
- New share issuances of 481,000 increased equity.
- Other comprehensive income increased equity by 493,000.
- Other factors increased equity by 44,799,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $2.70 Million | +2.43% |
| Share Repurchases | $6.00 Million | -5.39% |
| Share Issuances | $481.00K | +0.43% |
| Other Comprehensive Income | $493.00K | +0.44% |
| Other Changes | $44.80 Million | +40.28% |
| Total Change | $- | 61.78% |
Book Value vs Market Value Analysis
This analysis compares Delcath Systems Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.88x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.00x to 3.88x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $6621.62 | $10.80 | x |
| 2000-12-31 | $114080.14 | $10.80 | x |
| 2001-12-31 | $75056.72 | $10.80 | x |
| 2002-12-31 | $36373.11 | $10.80 | x |
| 2003-12-31 | $20095.32 | $10.80 | x |
| 2004-12-31 | $39924.39 | $10.80 | x |
| 2005-12-31 | $59989.98 | $10.80 | x |
| 2006-12-31 | $35188.23 | $10.80 | x |
| 2007-12-31 | $58465.65 | $10.80 | x |
| 2008-12-31 | $36066.70 | $10.80 | x |
| 2009-12-31 | $58953.71 | $10.80 | x |
| 2010-12-31 | $60710.62 | $10.80 | x |
| 2011-12-31 | $108315.35 | $10.80 | x |
| 2012-12-31 | $83024.90 | $10.80 | x |
| 2013-12-31 | $15049500.00 | $10.80 | x |
| 2014-12-31 | $6048333.33 | $10.80 | x |
| 2015-12-31 | $1228714.29 | $10.80 | x |
| 2016-12-31 | $-64782.61 | $10.80 | x |
| 2017-12-31 | $33764.94 | $10.80 | x |
| 2018-12-31 | $-391.59 | $10.80 | x |
| 2019-12-31 | $-245.44 | $10.80 | x |
| 2020-12-31 | $7.62 | $10.80 | x |
| 2021-12-31 | $1.67 | $10.80 | x |
| 2022-12-31 | $-0.66 | $10.80 | x |
| 2023-12-31 | $0.97 | $10.80 | x |
| 2024-12-31 | $2.41 | $10.80 | x |
| 2025-12-31 | $2.79 | $10.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Delcath Systems Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.17%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 1.11x
- Recent ROE (2.43%) is above the historical average (-334.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -116.33% | 0.00% | 0.00x | 1.22x | $-619.00K |
| 2000 | -19.57% | 0.00% | 0.00x | 1.21x | $-1.45 Million |
| 2001 | -58.13% | 0.00% | 0.00x | 1.05x | $-2.20 Million |
| 2002 | -110.40% | 0.00% | 0.00x | 1.11x | $-1.97 Million |
| 2003 | -103.69% | 0.00% | 0.00x | 1.12x | $-2.47 Million |
| 2004 | -48.13% | 0.00% | 0.00x | 1.08x | $-3.95 Million |
| 2005 | -22.74% | 0.00% | 0.00x | 1.03x | $-4.12 Million |
| 2006 | -135.32% | 0.00% | 0.00x | 1.08x | $-11.76 Million |
| 2007 | -22.30% | 0.00% | 0.00x | 1.10x | $-5.31 Million |
| 2008 | -67.26% | 0.00% | 0.00x | 1.11x | $-7.89 Million |
| 2009 | -92.84% | 0.00% | 0.00x | 1.55x | $-24.43 Million |
| 2010 | -160.53% | 0.00% | 0.00x | 1.74x | $-49.59 Million |
| 2011 | -118.32% | 0.00% | 0.00x | 1.35x | $-33.50 Million |
| 2012 | -259.22% | -14990.75% | 0.01x | 1.52x | $-53.87 Million |
| 2013 | -100.75% | -3838.48% | 0.02x | 1.23x | $-33.33 Million |
| 2014 | -95.79% | -1625.91% | 0.04x | 1.31x | $-19.20 Million |
| 2015 | -170.96% | -841.67% | 0.11x | 1.83x | $-15.56 Million |
| 2016 | 0.00% | -902.16% | 0.06x | 0.00x | $-17.82 Million |
| 2017 | -6654.42% | -1661.77% | 0.31x | 13.11x | $-45.18 Million |
| 2018 | 0.00% | -564.19% | 0.50x | 0.00x | $-17.73 Million |
| 2019 | 0.00% | -561.96% | 0.11x | 0.00x | $-8.24 Million |
| 2020 | -109.41% | -1467.56% | 0.05x | 1.57x | $-26.36 Million |
| 2021 | -214.60% | -721.49% | 0.11x | 2.77x | $-26.84 Million |
| 2022 | 0.00% | -1342.70% | 0.15x | 0.00x | $-35.92 Million |
| 2023 | -302.20% | -2308.86% | 0.05x | 2.45x | $-49.26 Million |
| 2024 | -38.38% | -70.92% | 0.49x | 1.11x | $-33.26 Million |
| 2025 | 2.43% | 3.17% | 0.69x | 1.11x | $-8.42 Million |
Industry Comparison
This section compares Delcath Systems Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Delcath Systems Inc (DCTH) | $111.22 Million | -116.33% | 0.11x | $334.77 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development… Read more